UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial

Journal of clinical lipidology, 2015-11, Vol.9 (6), p.758-769

2015

Volltextzugriff (PDF)

Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: Design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial

Journal of clinical lipidology, 2014-11, Vol.8 (6), p.554-561

2014

Volltextzugriff (PDF)

Safety Considerations with Niacin Therapy

The American journal of cardiology, 2007-03, Vol.99 (6), p.S22-S31

2007

Volltextzugriff (PDF)

An assessment by the Statin Intolerance Panel: 2014 update

Journal of clinical lipidology, 2014-05, Vol.8 (3), p.S72-S81

2014

Volltextzugriff (PDF)

Usefulness of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) in Women to Lower Triglyceride Levels (Results From the MARINE and ANCHOR Trials)

The American journal of cardiology, 2017-02, Vol.119 (3), p.397-403

2017

Volltextzugriff (PDF)

Triglyceride-lowering therapies reduce cardiovascular disease event risk in subjects with hypertriglyceridemia

Journal of clinical lipidology, 2016-07, Vol.10 (4), p.905-914

2016

Volltextzugriff (PDF)

Lipid-Altering Efficacy and Safety of Ezetimibe/Simvastatin Coadministered With Extended-Release Niacin in Patients With Type IIa or Type IIb Hyperlipidemia

Journal of the American College of Cardiology, 2008-04, Vol.51 (16), p.1564-1572

2008

Volltextzugriff (PDF)

Durability of Alirocumab Effect: Data From an Open-Label Extension to the ODYSSEY Program for Patients With Heterozygous Familial Hypercholesterolemia

Journal of clinical lipidology, 2017-05, Vol.11 (3), p.840-840

2017

Volltextzugriff (PDF)

Safety Considerations with Gastrointestinally Active Lipid-Lowering Drugs

The American journal of cardiology, 2007-03, Vol.99 (6), p.S47-S55

2007

Volltextzugriff (PDF)

MR Spectroscopy of Cholesteryl Ester in Human Atherosclerosis

JACC. Cardiovascular imaging, 2013-12, Vol.6 (12), p.1285-1286

Guyton, John R., MD

2013

Volltextzugriff (PDF)

Effects of Extended Release Niacin added to Simvastatin/Ezetemibe on Glucose and Insulin values in AIM HIGH

The American journal of medicine, 2016-03, Vol.129 (7), p.753.e13-753.e22

2016

Volltextzugriff (PDF)

Statin intolerance in a referral lipid clinic

Journal of clinical lipidology, 2016-07, Vol.10 (4), p.870-879.e3

2016

Volltextzugriff (PDF)

The Editor's Roundtable: Closing the Clinical Practice Gap—Using Evidence-Based Treatments for Managing Lipids

The American journal of cardiology, 2011-01, Vol.107 (2), p.230-242

2011

Volltextzugriff (PDF)

Long-Term Safety and Efficacy of Triple Combination Ezetimibe/Simvastatin Plus Extended-Release Niacin in Patients With Hyperlipidemia

The American journal of cardiology, 2010-02, Vol.105 (4), p.487-494

2010

Volltextzugriff (PDF)

Relationship of Lipoproteins to Cardiovascular Events

Journal of the American College of Cardiology, 2013-10, Vol.62 (17), p.1580-1584

2013

Volltextzugriff (PDF)

Risk of hospitalized rhabdomyolysis associated with lipid-lowering drugs in a real-world clinical setting

Journal of clinical lipidology, 2013-03, Vol.7 (2), p.102-108

2013

Volltextzugriff (PDF)

Adverse reactions of Achilles tendon xanthomas in three hypercholesterolemic patients after treatment intensification with niacin and bile acid sequestrants

Journal of clinical lipidology, 2013-03, Vol.7 (2), p.178-181

2013

Volltextzugriff (PDF)

Greater Dissociation of Apolipoprotein B and LDL Cholesterol Targets in Diabetes Versus Nondiabetes Patients Receiving Lipid-Lowering Therapy

Journal of clinical lipidology, 2011-05, Vol.5 (3), p.198-199

2011

Volltextzugriff (PDF)

Lower LDL-C values Should Be Reached to Normalize Apolipoprotein B Concentrations in Hypertriglyceridemic Patients Receiving Lipid-lowering Therapy

Journal of clinical lipidology, 2011-05, Vol.5 (3), p.199-200

2011

Volltextzugriff (PDF)

Inherited lipemic splenomegaly and the spectrum of apolipoprotein E p.Leu167del mutation phenotypic variation

Journal of clinical lipidology, 2013-11, Vol.7 (6), p.566-572

2013

Volltextzugriff (PDF)

Relationship Between HsCRP Reduction and LDL-C, Non-HDL-C, ApoB, and HDL-C in Hyperlipidemic Patients Treated with Ezetimibe/Simvastatin + Niaspan

Journal of clinical lipidology, 2011-05, Vol.5 (3), p.206-207

2011

Volltextzugriff (PDF)

Ezetimibe/Simvastatin + Extended Release Niacin Therapy Improves Attainment of Recommended Levels of LDL-C, Non-HDL-C, and ApoB in Hyperlipidemic Patients

Journal of clinical lipidology, 2011-05, Vol.5 (3), p.208-209

2011

Volltextzugriff (PDF)

Triglyceride-Lowering Therapies Reduce Cardiovascular Disease Event Risk in Subjects with Hypertriglyceridemia

Journal of clinical lipidology, 2015-05, Vol.9 (3), p.431-431

2015

Volltextzugriff (PDF)

The Editor's Roundtable: Lipid Management Beyond Statins—Reducing Residual Cardiovascular Risk

The American journal of cardiology, 2008-09, Vol.102 (5), p.559-567

2008

Volltextzugriff (PDF)

Elevation of fasting morning glucose relative to hemoglobin A1c in normoglycemic patients treated with niacin and with statins

Journal of clinical lipidology, 2012-03, Vol.6 (2), p.168-173

2012

Volltextzugriff (PDF)

1 – 25 von 127

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(125)
Mit Volltextzugriff
(122)

Publikationsform

Artikel
(125)
Buchkapitel
(2)

Sprache

Englisch
(127)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

7 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial

Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: Design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial

Safety Considerations with Niacin Therapy

An assessment by the Statin Intolerance Panel: 2014 update

Usefulness of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) in Women to Lower Triglyceride Levels (Results From the MARINE and ANCHOR Trials)

Triglyceride-lowering therapies reduce cardiovascular disease event risk in subjects with hypertriglyceridemia

Lipid-Altering Efficacy and Safety of Ezetimibe/Simvastatin Coadministered With Extended-Release Niacin in Patients With Type IIa or Type IIb Hyperlipidemia

Durability of Alirocumab Effect: Data From an Open-Label Extension to the ODYSSEY Program for Patients With Heterozygous Familial Hypercholesterolemia

Safety Considerations with Gastrointestinally Active Lipid-Lowering Drugs

MR Spectroscopy of Cholesteryl Ester in Human Atherosclerosis

Effects of Extended Release Niacin added to Simvastatin/Ezetemibe on Glucose and Insulin values in AIM HIGH

Statin intolerance in a referral lipid clinic

The Editor's Roundtable: Closing the Clinical Practice Gap—Using Evidence-Based Treatments for Managing Lipids

Long-Term Safety and Efficacy of Triple Combination Ezetimibe/Simvastatin Plus Extended-Release Niacin in Patients With Hyperlipidemia

Relationship of Lipoproteins to Cardiovascular Events

Risk of hospitalized rhabdomyolysis associated with lipid-lowering drugs in a real-world clinical setting

Adverse reactions of Achilles tendon xanthomas in three hypercholesterolemic patients after treatment intensification with niacin and bile acid sequestrants

Greater Dissociation of Apolipoprotein B and LDL Cholesterol Targets in Diabetes Versus Nondiabetes Patients Receiving Lipid-Lowering Therapy

Lower LDL-C values Should Be Reached to Normalize Apolipoprotein B Concentrations in Hypertriglyceridemic Patients Receiving Lipid-lowering Therapy

Inherited lipemic splenomegaly and the spectrum of apolipoprotein E p.Leu167del mutation phenotypic variation

Relationship Between HsCRP Reduction and LDL-C, Non-HDL-C, ApoB, and HDL-C in Hyperlipidemic Patients Treated with Ezetimibe/Simvastatin + Niaspan

Ezetimibe/Simvastatin + Extended Release Niacin Therapy Improves Attainment of Recommended Levels of LDL-C, Non-HDL-C, and ApoB in Hyperlipidemic Patients

Triglyceride-Lowering Therapies Reduce Cardiovascular Disease Event Risk in Subjects with Hypertriglyceridemia

The Editor's Roundtable: Lipid Management Beyond Statins—Reducing Residual Cardiovascular Risk

Elevation of fasting morning glucose relative to hemoglobin A1c in normoglycemic patients treated with niacin and with statins

Suchergebnisse filtern